Skip to main content
. 2019 Mar 22;11:64. doi: 10.3389/fnagi.2019.00064

Figure 3.

Figure 3

Cognitive testing and locomotor assessment of the affibody-administered APP/PS1 mice. (A,B) Assessment of sensorimotor abilities in 2xTg mice administered with the ZSYM73-ABD affibody molecule (red) or control (ZTaq)2-ABD (black) in (A) rotarod and (B) open field locomotor tests in which distance traveled, resting time, maximum velocity and average speed of mice were tested. (C) Radial arm maze testing (working memory assessment) of the ZSYM73-ABD (red) and (ZTaq)2-ABD (black) treated 2xTg mice. A group of wild type healthy control mice was included for comparison (blue). Animals were allowed to navigate the maze once per day for nine consecutive days. The number of errors that the mice performed on each testing day is plotted vs. the days of testing (p < 0.0001, by two-way ANOVA for treatment effect).